NYXH Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 1.97%, SMA50 -0.79%, SMA200 -20.52%). The stock’s 14-day RSI is 51.66 (neutral), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -60.4% below its high and over 14.63% above its low. Average 10-day trading volume of 16.08 thousand shares is below the 3-month average of 49.75 thousand, indicating normal recent market interest.

Nyxoah S.A. has 37.44 million shares outstanding. The public float is 18.73 million shares, elevated short interest at 0.92% of float. This equals 241.91 thousand shares. The short ratio is 1.92 days. Institutional investors hold 39.11% of the float. Insiders own 41.73%.

Nyxoah S.A. generated EPS of -$2.48 over the past year. Five-year average earnings growth is -34.68%. Wall Street analysts project EPS growth of 4.46% annually over the next five years. The latest quarter delivered EPS of -$0.74. The next quarter is forecast at -$0.64. Next year's EPS is expected at -$11.28. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $8.00. The high target offers 275.43% upside. The low target suggests 173.04% downside. The mean target is $9.80. This offers 234.47% upside. Nyxoah S.A. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 13, 2025, missed forecasts by 21.31%. The prior quarter beat by 1.61%. Over the last six quarters, Apple has recorded several small beats. These include 2.22% in August 06, 2024.

Nyxoah S.A. (NASDAQ:NYXH) closed at $2.93 USD, losing -$0.08 (-2.66%) from the previous close of $3.01. The stock is currently mid-range between its 52-week high and low $2.76 and $8.64. With a market capitalization of about $109.42 million, Nyxoah S.A. is classified as a micro-cap and shows market-like volatility (beta ~0.87). Key stats such as the average daily volume over the past year has been around 50.57 thousand shares, volume is running light vs its 52-week average. Headquartered in Mont-Saint-Guibert, None, Nyxoah S.A. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Olivier Taelman, the company employs approximately 183 people and listed since April 28, 2021. Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.

Nyxoah S.A. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.47. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Nyxoah S.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.71%, with price expected at $2.98 by May 12, 2026, within a range of $2.71 to $3.21 3-Month Outlook: Projected rise of 247.44%, reaching $10.18 by July 27, 2026, with a range of $9.19 to $11.00. 1-Year Outlook: Projected loss of -78.5%, with price at $0.63 by April 28, 2027, within a range of $0.00 to $0.00.

Nyxoah S.A. (NASDAQ:NYXH) shares are flat 2.83% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Nyxoah S.A. trading at a premium to the broader market with a P/E of -1.12. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.12, suggesting 484.3% upside. Our AI forecast model points to short-term strength (1.71% over two weeks), a medium-term rise (247.44% over three months), and a longer-term loss (-78.5% over one year), with expected trading ranges indicating moderate volatility.

Nyxoah S.A. trades at a P/E ratio of -1.12, slightly below the S&P 500 average, with a price-to-sales ratio of 9.41 and a price-to-book ratio of 2.06 suggesting the stock is closer to book value. The P/FCF stands at -1.35, also above market averages.